Boehringer Ingelheim Corporation to Announce Pivotal Phase III Hepatitis C Data for Faldaprevir* at American Association for Study of Liver Diseases Congress 2013
10/1/2013 10:10:14 AM
For media outside of the U.S.A., UK and Canada only
Ten abstracts featuring Boehringer Ingelheim’s investigational hepatitis C virus (HCV) protease inhibitor, faldaprevir*and polymerase inhibitor, deleobuvir* will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2013, 1-5 November, Washington.1
Help employers find you! Check out all the jobs and post your resume.